Key result
Prothrombinase Inhibition Percentage was significantly lower in patients with SLE alone (35.5%), SLE with LA (33.0%), and Behcet's disease (33.3%) compared to healthy volunteers (43.5%).
Why the study?
Does a novel assay using human thrombomodulin detect abnormalities in the protein C anticoagulant pathway in patients with SLE, BD, and thrombotic vasculitis compared to healthy volunteers?
Observational
Does a novel assay using human thrombomodulin detect abnormalities in the protein C anticoagulant pathway in patients with SLE, BD, and thrombotic vasculitis compared to healthy volunteers?
Absolute Event Rate: 35.5% vs 43.5%
p-value: p=0.036
A novel assay using human thrombomodulin demonstrated that abnormalities in the protein C anticoagulant pathway are present in patients with SLE and Behcet's disease.
Novel assay detects protein C pathway defects in SLE and Behcet's; hypothesis-generating, requires prospective validation before clinical use.
We developed a novel assay using human thrombomodulin (TM), which detected overall abnormalities in the protein C anticoagulant pathway (PC pathway). This assay indicates the degree of inhibition of prothrombinase by TM, which is represented as the percentage of prothrombinase inhibition by 25 ng/ml of TM, termed PIP25 (Prothrombinase Inhibition Percentage). We examined PIP25 in plasma samples from patients with systemic lupus erythematosus (SLE) with or without lupus anticoagulant (LA), patients with Behcet's disease (BD), and patients with miscellaneous thrombotic vasculitis and compared these with the PIP25 of plasma samples from healthy volunteers in Japan. The PIP25S were significantly lower in SLE alone (35.5 +/- 12.8%, P = 0.036) and SLE with LA (33.0 +/- 13.3%, P = 0.030) and BD (33.3 +/- 13.4%, P = 0.010) than those in healthy volunteers (43.5 +/- 10.7%). There was no significance between healthy PIP25 and those with miscellaneous thrombotic vasculitis (44.2 +/- 8.4%, P = 0.823). These results suggest that the abnormalities of the protein C anticoagulant pathway were present in patients with SLE(LA) and BD.
No takes yet. Share an insight, caveat, or question.
Mohri et al. (1997) conducted an observational in Systemic lupus erythematosus, Behcet's disease, thrombotic vasculitis. Systemic lupus erythematosus or Behcet's disease vs. Healthy volunteers was evaluated on Prothrombinase Inhibition Percentage (PIP25) (p=0.036). Prothrombinase Inhibition Percentage was significantly lower in patients with SLE alone (35.5%), SLE with LA (33.0%), and Behcet's disease (33.3%) compared to healthy volunteers (43.5%).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: